Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem

Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis. This combina...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Griffith, David C., Sabet, Mojgan, Tarazi, Ziad, Lomovskaya, Olga, Dudley, Michael N.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2018
Schlagworte:
Experimental Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325214/
https://ncbi.nlm.nih.gov/pubmed/30397063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01659-18
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge